It is unsurprising that statins have become the most commonly prescribed drugs in many parts of the world, given the extraordinarily large and complete evidence base that supports their use. Their role in reducing cardiovascular (CV) events in both primary and secondary prevention is clear and predictable, with recent data extending their utility across most ages, and for most CV outcomes. Latterly, there has also been direct evidence of the benefits of more intensive treatment targets benefiting patients with established cardiovascular disease (CVD).
